Literature DB >> 35228693

Bispecific antiviral neutralizing antibodies are twice as nice.

James E Crowe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35228693     DOI： 10.1038/s41590-022-01147-9

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   31.250


× No keyword cloud information.
  2 in total

1.  An engineered bispecific human monoclonal antibody against SARS-CoV-2.

Authors:  Zhaohui Li; Shihua Li; Gen Zhang; Weiyu Peng; Zhen Chang; Xue Zhang; Zheng Fan; Yan Chai; Feiran Wang; Xin Zhao; Dedong Li; Rong Zhang; Zhanlong He; Weiwei Zou; Ke Xu; Wenwen Lei; Peipei Liu; Junfeng Hao; Jingjing Zhang; Litao Sun; Guizhen Wu; Shuguang Tan; George Fu Gao; Feng Gao; Yan Wu
Journal:  Nat Immunol       Date:  2022-02-28       Impact factor: 31.250

2.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.

Authors:  Laura A VanBlargan; John M Errico; Peter J Halfmann; Seth J Zost; James E Crowe; Lisa A Purcell; Yoshihiro Kawaoka; Davide Corti; Daved H Fremont; Michael S Diamond
Journal:  Nat Med       Date:  2022-01-19       Impact factor: 87.241
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.